生命科学资讯
生物技术与制药领域的最新动态
Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever
前Spero高管因抗生素疗效声明被美国证监会罚款
Former Spero execs fined by SEC over antibiotic efficacy claims
默克-莫德纳癌症疫苗五年内持续降低黑色素瘤风险49%
Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years
Boundless最终放弃对两种疗效平平的癌症药物进行联合治疗。
Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs
百时美施贵宝联手微软AI检测网络,加速肺癌诊断进程。
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis
田边三菱制药口服药物在罕见病三期研究中取得成效,但具体细节仍不明朗。
Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark
辉瑞签署5.3亿美元协议,将在两个项目中应用诺瓦瓦克斯疫苗佐剂技术。
Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs
葛兰素史克斥资22亿美元收购Rapt,获得其针对Xolair的二期食物过敏挑战者药物。
GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair
ARPA-H主任展望疫苗之外未来,致力于在生物技术竞赛中“战胜中国”。
ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China
雅培与AtaCor合作开发血管外除颤器植入技术。
Abbott, AtaCor join forces on extravascular defibrillator implant
FDA授予iRegene公司NouvNeu001再生医学先进疗法认定,巩固其作为全球首个同时获得FTD与RMAT认证的iPSC疗法的领先地位。
FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions
阿斯利康签署6.3亿美元协议,获得AbelZeta装甲CAR-T剩余权益。
AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta
免疫生物技术公司Agomab与专注眼科的SpyGlass成为最新一批公布IPO计划的生物科技企业。
Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions
韦丹塔大幅裁员以资助铅菌鸡尾酒疗法项目。
Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program
Exelixis CEO:单药战略旨在成为美国前五大实体瘤公司。
Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO
滑梯与梯子——小罗伯特·F·肯尼迪继续改革疾控中心疫苗小组
Chutes & Ladders—RFK Jr. continues overhaul of CDC vaccine panel
ImmunityBio宣布其现成CAR-NK疗法试验中实现15个月完全缓解。
ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial
JPM26:中外制药借力美国生物制药行业,追求新科学与品牌知名度
JPM26: Chugai chases new science and name recognition from US biopharma industry
JPM26:安斯泰来CEO抵制"救援并购",60亿美元Xtandi专利悬崖逼近
JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears